Fjarde Ap Fonden Abb Vie Inc. Transaction History

Fjarde Ap Fonden

$9.8 Billion
Q3 2024

A detailed history of Fjarde Ap Fonden transactions in Abb Vie Inc. stock. As of the latest transaction made, Fjarde Ap Fonden holds 481,084 shares of ABBV stock, worth $86.4 Million. This represents 0.97% of its overall portfolio holdings.

Number of Shares

481,084

Previous 467,784 2.84%

Holding current value

$86.4 Million

Previous $85.2 Million 11.53%

% of portfolio

0.97%

Previous 0.94%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$163.84 - $199.33 $2.18 Million - $2.65 Million	13,300 Added 2.84%	481,084 $95 Million
Q1 2024 Apr 25, 2024	BUY	$159.82 - $182.1 $2.62 Million - $2.98 Million	16,365 Added 3.63%	467,784 $85.2 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $1.2 Million - $1.35 Million	-8,700 Reduced 1.89%	451,419 $70 Million
Q3 2023 Oct 23, 2023	SELL	$133.59 - $154.65 $1.92 Million - $2.23 Million	-14,400 Reduced 3.03%	460,119 $68.6 Million
Q2 2023 Aug 02, 2023	BUY	$132.51 - $164.9 $927,569 - $1.15 Million	7,000 Added 1.5%	474,519 $63.9 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $939,820 - $1.08 Million	-6,499 Reduced 1.37%	467,519 $74.5 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $2.03 Million - $2.43 Million	14,667 Added 3.19%	474,018 $76.7 Million
Q2 2022 Aug 11, 2022	BUY	$137.62 - $174.96 $674,338 - $857,304	4,900 Added 1.08%	459,351 $70.4 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $1.4 Million - $1.74 Million	-10,602 Reduced 2.28%	454,451 $73.7 Million
Q4 2021 Feb 15, 2022	SELL	$107.43 - $135.93 $3.27 Million - $4.14 Million	-30,423 Reduced 6.14%	465,053 $63 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $659,680 - $748,836	-6,200 Reduced 1.24%	495,476 $53.4 Million
Q2 2021 Aug 12, 2021	SELL	$105.21 - $117.21 $2.14 Million - $2.38 Million	-20,300 Reduced 3.89%	501,676 $56.5 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $306,900 - $337,860	3,000 Added 0.58%	521,976 $56.5 Million
Q4 2020 Feb 12, 2021	SELL	$80.49 - $108.67 $1.64 Million - $2.22 Million	-20,400 Reduced 3.78%	518,976 $55.6 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $1.52 Million - $1.78 Million	17,700 Added 3.39%	539,376 $47.2 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $7.95 Million - $10.6 Million	108,397 Added 26.23%	521,676 $51.2 Million
Q1 2020 May 11, 2020	SELL	$64.5 - $97.79 $1.46 Million - $2.22 Million	-22,700 Reduced 5.21%	413,279 $31.5 Million
Q4 2019 Feb 10, 2020	SELL	$72.13 - $90.25 $158,686 - $198,550	-2,200 Reduced 0.5%	435,979 $38.6 Million
Q3 2019 Oct 31, 2019	SELL	$62.98 - $75.72 $110,655 - $133,040	-1,757 Reduced 0.4%	438,179 $33.2 Million
Q2 2019 Jul 17, 2019	SELL	$65.7 - $83.98 $1.28 Million - $1.64 Million	-19,500 Reduced 4.24%	439,936 $32 Million
Q1 2019 Apr 29, 2019	BUY	$77.14 - $90.79 $7.66 Million - $9.01 Million	99,257 Added 27.56%	459,436 $37 Million
Q4 2018 Jan 31, 2019	SELL	$77.85 - $96.01 $3.02 Million - $3.73 Million	-38,800 Reduced 9.72%	360,179 $33.2 Million
Q3 2018 Nov 09, 2018	SELL	$88.91 - $98.84 $1.67 Million - $1.86 Million	-18,786 Reduced 4.5%	398,979 $37.7 Million
Q2 2018 Jul 12, 2018	SELL	$89.78 - $106.23 $3.03 Million - $3.58 Million	-33,734 Reduced 7.47%	417,765 $38.7 Million
Q1 2018 May 07, 2018	BUY	$92.01 - $123.21 $341,725 - $457,601	3,714 Added 0.83%	451,499 $42.7 Million
Q4 2017 Feb 12, 2018	BUY	$89.56 - $98.21 $6.41 Million - $7.03 Million	71,575 Added 19.03%	447,785 $43.3 Million
Q3 2017 Nov 07, 2017	BUY	$69.85 - $89.22 $981,043 - $1.25 Million	14,045 Added 3.88%	376,210 $33.4 Million
Q2 2017 Aug 08, 2017	BUY	N/A	362,165	362,165 $26.3 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $317B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.

Account